Form 4: Exact Sciences Executive Sells Shares Post-Merger

Jacob Orville, EVP at Exact Sciences, reported the disposition of common stock, stock options, and restricted stock units following the company's merger with Abbott Laboratories' subsidiary.

Summary

• Jacob A. Orville, EVP, GM, Screening of Exact Sciences Corp., reported transactions related to the company's merger with Badger Merger Sub I, Inc., a wholly-owned subsidiary of Abbott Laboratories, effective March 23, 2026.
• At the effective time of the merger, 53,323 performance-based restricted stock units (PSUs) were deemed fully vested based on actual achievement as of November 19, 2025, and converted into the right to receive $105.00 cash per share.
• Concurrently, 153,726 shares of common stock directly held and 1,774 shares held indirectly in a 401(k) plan were converted into the right to receive the merger consideration of $105.00 cash per share.
• 6,581 stock options with an exercise price of $98.18 were cancelled and converted into a cash payment equal to the number of shares multiplied by the difference between the merger consideration ($105.00) and the exercise price.
• 38,707 restricted stock units (RSUs) were disposed of. RSUs granted before November 19, 2025, were converted to cash, while those granted on or after November 19, 2025, were assumed by Abbott Laboratories.
• Following these transactions, Mr. Orville holds no direct or indirect beneficial ownership in Exact Sciences Corp.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting the administrative details of an executive's equity transactions following the completed acquisition of Exact Sciences by Abbott Laboratories. The cash payout for equity awards is a positive for the executive.

Positives

• The reporting executive received a cash payout for all vested common stock, performance-based restricted stock units (PSUs), and in-the-money stock options as a result of the merger.
• Performance conditions for PSUs were deemed satisfied based on actual achievement as of November 19, 2025, leading to full vesting of 53,323 PSUs.

Negatives

• The reporting executive no longer holds any direct or indirect beneficial ownership in Exact Sciences Corp. following its acquisition by Abbott Laboratories.

Future Outlook

NA

Industry Context

StockSavvy.ai notes this Form 4 reflects the finalization of a significant acquisition in the diagnostics and healthcare sector, where Exact Sciences, a leader in cancer screening, was acquired by Abbott Laboratories, a diversified healthcare giant. This transaction consolidates market share and integrates Exact Sciences' innovative screening technologies into Abbott's broader portfolio.

Comparison to Industry Standards

• The $105.00 per share merger consideration for Exact Sciences (EXAS) can be compared to recent acquisitions in the diagnostics and medical technology sector. For example, Siemens Healthineers' acquisition of Varian Medical Systems in 2020 for $16.4 billion, or Danaher's acquisition of Cytiva from GE Life Sciences for $21.4 billion in 2020, involved significant premiums reflecting strategic value and market leadership.
• The valuation multiple implied by the $105.00 per share would need to be assessed against EXAS's historical financials (e.g., revenue, EBITDA multiples) and compared to similar transactions involving companies like Guardant Health or Natera in the precision oncology space, or broader diagnostic companies like Quest Diagnostics or LabCorp.
• The structure of equity award treatment (cash-out for options below merger price, cash-out for PSUs, assumption for certain RSUs) is standard practice in M&A, aiming to provide liquidity to employees while retaining key talent post-acquisition.

Related Party Transactions

• The disposition of common stock, stock options, and restricted stock units by Jacob A. Orville, an EVP of Exact Sciences, is a direct consequence of the merger of Exact Sciences with a subsidiary of Abbott Laboratories.

Stakeholder Impact

• Shareholders (of Exact Sciences): Received $105.00 cash per share, indicating a liquidity event and a premium for their investment.
• Employees (of Exact Sciences, including the reporting person): Equity awards were settled in cash or assumed by Abbott, providing financial benefit and clarity on future compensation.
• Abbott Laboratories: Acquired Exact Sciences, expanding its diagnostics portfolio and market presence.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Form 4, Insider Trading, Stock Options, Restricted Stock Units, PSUs, Equity Compensation, Corporate Acquisition